Morgan Stanley analyst Kristine Liwag maintained a Sell rating on Hexcel (HXL – Research Report) yesterday and set a price target of $61.00.

The U.S. Food and Drug Administration approved Symvess, the first acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent ...

Morgan Stanley maintains a solid balance sheet, with assets reaching $1.26t and shareholder equity rising to $103.6b. Read ...

Morgan Stanley’s stock (NYSE: MS) gained over 30% year-to-date. This compares to rival Goldman Sachs stock, which has seen ...

Stephen Luczo has resigned from Morgan Stanley’s Board of Directors for personal reasons, effective December 31, 2024, with no disagreements cited with the company. Following his resignation and James ...

Morgan Stanley has teamed up with cross-border money transmitter Wise to settle foreign-exchange payments for the investment bank’s corporate clients, a service traditionally led by money-center ...

Morgan Stanley highlighted 2025 outlook on Communication software stocks. Nice (NICE) remains its favored name, while ...

Shares of Morgan Stanley MS slumped 0.45% to $120.50 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising 0.04% to ...

The story for consumer credit this year was stabilization as higher delinquencies slid to their slowest pace in three years, ...

But these qualities are less prevalent here than at Morgan Stanley Advantage MPAIX, a tamer sibling to this strategy. The portfolio managers’ pursuit of unique business models often leads them ...

While we don’t expect ASICs [application specific integrated circuit] to gain share in 2025, we have enthusiasm longer-term,” ...